These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 15547747)

  • 1. Utility of initial MRI for predicting extent of residual disease after neoadjuvant chemotherapy: analysis of 70 breast cancer patients.
    Murata Y; Ogawa Y; Yoshida S; Kubota K; Itoh S; Fukumoto M; Nishioka A; Moriki T; Maeda H; Tanaka Y
    Oncol Rep; 2004 Dec; 12(6):1257-62. PubMed ID: 15547747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histologic breast cancer extent after neoadjuvant chemotherapy: comparison with multidetector-row CT and dynamic MRI.
    Tozaki M; Uno S; Kobayashi T; Aiba K; Yoshida K; Takeyama H; Shioya H; Tabei I; Toriumi Y; Suzuki M; Kawakami M; Fukuda K
    Radiat Med; 2004; 22(4):246-53. PubMed ID: 15468945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer.
    Goorts B; Dreuning KMA; Houwers JB; Kooreman LFS; Boerma EG; Mann RM; Lobbes MBI; Smidt ML
    Breast Cancer Res; 2018 Apr; 20(1):34. PubMed ID: 29669584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative evaluation of residual tumor extent by three-dimensional magnetic resonance imaging in breast cancer patients treated with neoadjuvant chemotherapy.
    Akazawa K; Tamaki Y; Taguchi T; Tanji Y; Miyoshi Y; Kim SJ; Ueda S; Yanagisawa T; Sato Y; Tamura S; Noguchi S
    Breast J; 2006; 12(2):130-7. PubMed ID: 16509837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Residual microcalcifications after neoadjuvant chemotherapy for locally advanced breast cancer: comparison of the accuracies of mammography and MRI in predicting pathological residual tumor.
    An YY; Kim SH; Kang BJ
    World J Surg Oncol; 2017 Nov; 15(1):198. PubMed ID: 29110671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic resonance imaging evaluation of residual tumors in breast cancer after neoadjuvant chemotherapy: surgical implications.
    Zhou J; Li G; Sheng F; Qiao P; Zhang H; Xing X
    Acta Radiol; 2016 May; 57(5):529-37. PubMed ID: 26231950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective factors to raise diagnostic performance of breast MRI for diagnosing pathologic complete response in breast cancer patients after neoadjuvant chemotherapy.
    Choi BB; Kim SH
    Acta Radiol; 2015 Jul; 56(7):790-7. PubMed ID: 24951616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Value of dynamic contrast-enhanced MRI in assessment of early response to neoadjuvant chemotherapy in breast cancer].
    Wang XH; Peng WJ; Xin C; Tan HN; Gu YJ; Tang F; Mao J
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):539-43. PubMed ID: 21029700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
    McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
    Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Performances of breast magnetic resonance imaging in the context of neoadjuvant chemotherapy for breast cancer to predict pathological complete response].
    Brisson C; Diguisto C; Vildé A; Body G; Arbion F; Leveque J; Ouldamer L
    J Gynecol Obstet Hum Reprod; 2017 Feb; 46(2):147-154. PubMed ID: 28403971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new histological therapeutic classification system to predict eradicated and residual lymph nodes in breast cancer after neoadjuvant chemotherapy.
    Morohashi S; Yoshizawa T; Seino H; Hirai H; Haga T; Ota R; Wu Y; Yoshida E; Hakamada K; Kijima H
    Oncol Rep; 2016 May; 35(5):2592-8. PubMed ID: 26935647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of
    Hunt KN; Conners AL; Goetz MP; O'Connor MK; Suman V; Kalari K; Weinshilboum R; Wang L; Carter J; McLaughlin S; Aspitia AM; Gray R; Northfelt D; Boughey JC
    AJR Am J Roentgenol; 2019 Oct; 213(4):932-943. PubMed ID: 31166752
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.
    Kim MJ; Kim EK; Park S; Moon HJ; Kim SI; Park BW
    Acta Radiol; 2015 Sep; 56(9):1069-77. PubMed ID: 25228161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer.
    Hieken TJ; Boughey JC; Jones KN; Shah SS; Glazebrook KN
    Ann Surg Oncol; 2013 Oct; 20(10):3199-204. PubMed ID: 23846781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer.
    Charehbili A; Wasser MN; Smit VT; Putter H; van Leeuwen-Stok AE; Meershoek-Klein Kranenbarg WM; Liefers GJ; van de Velde CJ; Nortier JW; Kroep JR
    Eur J Surg Oncol; 2014 Oct; 40(10):1216-21. PubMed ID: 25150151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy.
    Belli P; Costantini M; Malaspina C; Magistrelli A; LaTorre G; Bonomo L
    Clin Radiol; 2006 Nov; 61(11):946-53. PubMed ID: 17018307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical usefulness of AJCC response criteria for neoadjuvant chemotherapy in breast cancer.
    Keam B; Im SA; Lim Y; Han SW; Moon HG; Oh DY; Cho N; Lee SH; Han W; Moon WK; Kim DW; Kim TY; Park IA; Noh DY
    Ann Surg Oncol; 2013 Jul; 20(7):2242-9. PubMed ID: 23529780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnetic resonance imaging enhancement features before and after neoadjuvant chemotherapy in patients with breast cancer: a predictive value for responders.
    Kang DK; Kim TH; Han TS; Kim KS; Yim H
    J Comput Assist Tomogr; 2013; 37(3):432-9. PubMed ID: 23674017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive Clinicopathologic and Dynamic Contrast-Enhanced MRI Findings for Tumor Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    Eom HJ; Cha JH; Choi WJ; Chae EY; Shin HJ; Kim HH
    AJR Am J Roentgenol; 2017 Jun; 208(6):W225-W230. PubMed ID: 28350486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of DCE-MRI for early evaluation of pathological complete response to neoadjuvant chemotherapy in resectable primary breast cancer: A single-center prospective study.
    Sun YS; He YJ; Li J; Li YL; Li XT; Lu AP; Fan ZQ; Cao K; Ouyang T
    Breast; 2016 Dec; 30():80-86. PubMed ID: 27652977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.